CA Patent

CA2995344C — Human anti-vegfr-2/kdr antibodies

Assigned to Kadmon Corp LLC · Expires 2021-05-04 · 5y expired

What this patent protects

The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

USPTO Abstract

The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents.

Drugs covered by this patent

Patent Metadata

Patent number
CA2995344C
Jurisdiction
CA
Classification
—
Expires
2021-05-04
Drug substance claim
No
Drug product claim
No
Assignee
Kadmon Corp LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.